[Truncated] Deep vein thrombosis is a major health problem that carries the immediate and potentially fatal risk of pulmonary embolism. The post-thrombotic syndrome (PTS) is a long-term complication of deep vein thrombosis (DVT) and affects 20%-82% of patients. One quarter to one third of these suffer the severe forms of PTS which are lipodermatosclerosis and venous leg ulceration. Venous leg ulcers are a difficult clinical problem because they are slow to heal, and have a high recurrence rate that is reported in both Europe and Australia to be as high as 76%.
Chronic venous disease is a major burden on health care resources impacting on both community and in-patient care. The global costs for treatment have been estimated at between $750 million and $1 billion per year. The cost of the social implications and the impact on the quality of life have not been effectively measured.
The venous changes that occur as the result of a DVT are variable, however the severity of these changes cannot be predicted by the extent of the original thrombus or the associated haemodynamic changes. It is not known why some patients develop lipodermatosclerosis and ulceration following a DVT and why others remain without symptoms.
A significant number of patients who develop venous thrombosis have been found to have hypercoagulable states. Many of these have a genetic cause, especially in patients with recurring deep vein thrombosis, who may possess multiple genetic abnormalities.
|Qualification||Doctor of Philosophy|
|Publication status||Unpublished - 2010|